Safflower Yellow Pigments in Coronary Heart Disease: Mechanisms, Applications, and Future Perspectives

Abstract

Coronary heart disease is an ischemic condition characterized by vascular stenosis or obstruction caused by coronary atherosclerosis, resulting in myocardial ischemia, hypoxia, or necrosis. It is one of the leading causes of death in both urban and rural populations in China. Safflower yellow pigments, the main active components of the traditional Chinese herbal medicine safflower, are primarily composed of quinochalcone compounds, including hydroxysafflor yellow A and anhydrosafflor yellow B—of which hydroxysafflor yellow A is the principal component. Studies have demonstrated that these pigments can improve myocardial ischemia, reduce ischemia-reperfusion injury, alleviate atherosclerotic damage, and address risk factors associated with coronary heart disease. This review aimed to systematically and comprehensively summarize the mechanisms of action of safflower yellow pigments and their active components in the context of coronary heart disease and its related risk factors.

Keywords

Carthamus tinctorius / Safflower yellow pigments / Coronary heart disease / Hydroxysafflor yellow A / Anhydrosafflor yellow B / Risk factors

References

[1] Liu MB, He XY, Yang XH, Wang ZW. Interpretation of Report on Cardiovascular Health and Diseases in China 2023. Chin J Cardiovasc Med 2024; 29(4):305-324. doi:10.3969/j.issn.1007-5410.2024.04.002.

[2] Yue S, Tang Y, Li S, Duan JA. Chemical and biological properties of quinochalcone C-glycosides from the florets of Carthamus tinctorius. Molecules 2013; 18(12):15220-15254. doi:10.3390/molecules 181215220, PMID:24335575.

[3] Zhang XM, Xiao JH, Wang Y, Tang YP, Yue SJ. Research progress in chemical constituents and pigment extraction process of Carthami Flos. Zhongguo Zhong Yao Za Zhi 2024; 49(7):1725-1740. doi:10.19540/j.cnki.cjcmm.20240105.201, PMID:38812185.

[4] National Pharmacopoeia Commission. Pharmacopoeia of the People’s Republic of China. Volume I. Beijing: China Medical Science Press; 2025:157-158.

[5] Chen KJ, Fu CG, Cong WH, Liu Y. Chinese Expert Consensus on the Clinical Application of safflower yellow pigments. Chin J Integr Med 2017; 37(10):1167-1173. doi:10.7661/j.cjim.20170621.182.

[6] The Cardiovascular Branch of the China Association of Chinese Medicine. Traditional Chinese Medicine Diagnosis and Treatment Guidelines for Stable Angina Pectoris of Coronary Heart Disease. J Tradit Chin Med 2019; 60(21):1880-1890. doi:10.13288/j.11-2166/r.2019.21.015.

[7] Yue S, Tang Y, Xu C, Li S, Zhu Y, Duan JA. Two new quinochalcone C-glycosides from the florets of Carthamus tinctorius. Int J Mol Sci 2014; 15(9):16760-16771. doi:10.3390/ijms150916760, PMID:2524 7575.

[8] Yue SJ, Qu C, Zhang PX, Tang YP, Jin Y, Jiang JS, et al. Carthorquinosides A and B, Quinochalcone C-Glycosides with Diverse Dimeric Skeletons from Carthamus tinctorius. J Nat Prod 2016; 79(10):2644-2651. doi:10.1021/acs.jnatprod.6b00561, PMID:27748595.

[9] Zhang HF, Guo JX, Huang LS, Ping QN. Pharmacokinetics of hydroxysafflor yellow A in rats. J China Pharm Univ 2006; 37(5):456-460.

[10] Huang YR, Zhang JQ, Shi MX, Wang TT, Zhao H. Study on the pharmacokinetics of hydroxysafflower yellow A in rats by tail vein injection. ZhongGou Lin Chuang Yao Li Xue Za Zhi 2020; 36(3):332-334+340. doi:10.13699/j.cnki.1001-6821.2020.03.031.

[11] Zhao X, Gu S, Wang X, Cai Y, Zhou Z. The Safety, Tolerability, and Pharmacokinetics of Active Ingredients From Hydroxysafflor Yellow A in Healthy Chinese Volunteers. Clin Pharmacol Drug Dev 2025; 14(1):79-86. doi:10.1002/cpdd.1487, PMID:39551721.

[12] Yue S, Wu L, Qu C, Tang Y, Jin Y, Li S, et al. Development and validation of a UFLC-MS/MS method for the determination of anhydrosafflor yellow B in rat plasma and its application to pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2015; 1003:54-59. doi:10.1016/j.jchromb.2015.09.013, PMID:26409263.

[13] Li Y, Zhang ZY, Zhang JL. Determination of hydroxysafflor yellow A in rat plasma and tissues by high-performance liquid chromatography after oral administration of safflower extract or safflor yellow. Biomed Chromatogr 2007; 21(3):326-334. doi:10.1002/bmc.769, PMID:17221936.

[14] Zou T.Study on pharmacokinetics of safflor yellow powder injection [Dissertation]. Harbin: Heilongjiang University of Chinese Medicine; 2011.

[15] Jin Y, Wu L, Tang Y, Cao Y, Li S, Shen J, et al. UFLC-Q-TOF/MS based screening and identification of the metabolites in plasma, bile, urine and feces of normal and blood stasis rats after oral administration of hydroxysafflor yellow A. J Chromatogr B Analyt Technol Biomed Life Sci 2016;1012-1013:124-129. doi:10.1016/j.jchromb.2016.01.023, PMID:26827279.

[16] Yue S, Wu L, Wang J, Tang Y, Qu C, Shi X, et al. Metabolic profile of anhydrosafflor yellow B in rats by ultra-fast liquid chromatography/ quadrupole time-of-flight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2016; 1014:37-44. doi:10.1016/j.jchromb2016.01.047., PMID:26871281.

[17] Chen C, Wu QS, Li HT. The interventional effect of safflower yellow sodium chloride on cardiac function and hemorrheologic in patients with myocardial infarction. Chin Hosp Pharm J 2014; 34(17):1501-1504. doi:10.13286/j.cnki.chinhosppharmacyj.2014.17.20.

[18] Jin YF. Effect of Safflower Yellow for Injection on Myocardial Ischemia of Coronary Heart Disease and Its Influence on Hemorheological Indexes. Guide of China Medicine 2020; 18(32):126-127. doi:10.15912/j.cnki.gocm.2020.32.060.

[19] Zhang Q, Peng JH, Zhang XN. A clinical study of Safflower Yellow injection in treating coronary heart disease angina pectoris with Xinblood stagnation syndrome. Chin J Integr Med 2005; 11(3):222-225. doi:10.1007/BF02836509, PMID:16181539.

[20] Wang T, Fu FH, Han B, Zhu M, Li GS, Liu K. Protection and mechanisms of hydroxysafflor yellow A on experimental myocardial infarction in rats. Chin Tradit Herb Drugs 2007; 38(12):1853-1856.

[21] Li XZ, Liu JX, Shang XH, Fu JH. Protective effects of hydroxysafflor yellow A on acute myocardial ischemia in dogs. Chin Pharmacol Bull 2006; 22(5):533-537.

[22] Qi Y, Qin WY, Song DF, Liu H, Zhao JM. The experimental study of carithamine on myocardial ischemia. Pharmacology and Clinics of Chinese Materia Medic 2012; 28(5):21-23.

[23] Nie PH, Zhang L, Zhang WH, Rong WF, Zhi JM. The effects of hydroxysafflor yellow A on blood pressure and cardiac function. J Ethnopharmacol 2012; 139(3):746-750. doi:10.1016/j.jep.2011.11.054, PMID: 22197825.

[24] Zhang Y, Chen C, Liu Q, Qin YY, Gao H. Protection Effect of Saffower Yellower in Acute Myocardial Ischemic Rats. Chin J Exp Tradit Med Formulae 2012; 18(16):282-284.

[25] Liu L, Wei Y, Pu ZJ, Tang YH, Se WY, Wu AP, et al. Effect of safflor yellow on myocardial ischemia and hemodynamics in dogs. China Medicine and Pharmacy 2013; 3(24):26-28.

[26] Wei XJ, Chang R. Effect of safflower yellow pigments on Cardiac Function and Infarct Size in Rats after Myocardial Infarction. Chin J Gerontol 2016; 36(6):1296-1298. doi:10.3969/j.issn.1005-9202.2016.06.007.

[27] Niu YW, Wang HZ, Zhang YJ. Effect of safflower yellow pigments for Injection Combined with Nicorandil in the Treatment of Coronary Heart Disease with Myocardial Ischemia and Its Influence on the Levels of Blood Lipids and Inflammatory Factors. Lab Med Chin 2023;20( 2):269-271. doi:10.3969/j.issn.1672-9455.2023.02.032.

[28] Liu XH, Li LQ, Lu WH, Lai CL. Plasma Levels of ET, MMP-9, hs-CRP, Platelet Aggregation Rate in Patients with Coronary Heart Disease and the Interventional Effect of safflower yellow pigments. Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease 2011; 9(9):1036-1038.

[29] Zou J, Wang N, Liu M, Bai Y, Wang H, Liu K, et al. Nucleolin mediated pro-angiogenic role of Hydroxysafflor Yellow A in ischaemic cardiac dysfunction: Post-transcriptional regulation of VEGF-A and MMP-9. J Cell Mol Med 2018; 22(5):2692-2705. doi:10.1111/jcmm.13552, PMID:29512890.

[30] Liang WL, Cai MR, Cui S, Zhang MQ, Wu YH, Ou WJ, et al. Doseeffect relationship between anti-myocardial ischemia and anticoagulation of safflower yellow injection. Central South Pharmacy 2022; 20(6):1322-1328. doi:10.7539/j.issn.1672-2981.2022.06.017.

[31] Li LM, Cao C, Han X, Fu JH, Li L, Zhang Q, et al. Effects of hydroxysafflor yellow A on oxidative stress and apoptosis of H9C2 cardiomyocytes injured by oxygen-glucose deprivation/reperfusion. Chin J Comp Med 2023; 33(3):9-16. doi:10.3969/j.issn.1671-7856.2023.03.002.

[32] He Y. Effect and Mechanism of Hydroxysafflor Yellow A on Myocardial ischemic injury Through Nrf2/Keapl/NF-κB Signal Pathway [Dissertation]. Nanjing: Nanjing University of Chinese Medicine; 2022.

[33] Xu AB, Liu JG, Zhang J, Li JX. Hydroxysafflor yellow A for ameliorating injury of myocardial ischemia/reperfusion in SD rats. Chin J Evid Based Cardiovasc Med 2014; 6(6):733-736. doi:10.3969 /j.1674-4055.2014.06.23.

[34] Liu YG, Li FJ, Tang F. Protective effect of hydroxysaffloryellow A on rats with myocardial ischemia and reperfusion injury. Pharmacology and Clinics of Chinese Materia Medica 2015; 31(1):71-74. doi:10.13412/j. cnki.zyyl.2015.01.023.

[35] Zhang JJ, Zhang ZY, Wang N. Effect and mechanism of action of hydroxysafflor yellow A on myocardial ischemia-reperfusion injury in rats. Chin J Hosp Pharm 2012; 32(19):1526-1530. doi:10.13286/j. cnki.chinhosppharmacyj.2012.19.006.

[36] Zhang Y, Zhang Y. Effects of Hydroxysafflor Yellow A on Inflammatory Factors and NF-κB in Rats with Myocardial Ischemia-reperfusion Injury. Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascuiar Disease 2020; 18(16):2603-2607. doi:10.12102/j.issn.1672-1349.2020.16.009.

[37] Han D, Wei J, Zhang R, Ma W, Shen C, Feng Y, et al. Hydroxysafflor yellow A alleviates myocardial ischemia/reperfusion in hyperlipidemic animals through the suppression of TLR4 signaling. Sci Rep 2016; 6:35319. doi:10.1038/srep35319, PMID:27731393.

[38] Yu H, Qu L. Protective effect of hydroxysafflor yellow A on myocardial ischemia/reperfusion injury in rats based on p38MAPK/ SERCA2α pathway. Chin J Immunol 2023; 39(7):1395-1401,1408. doi:10.3969/j.issn.1000-484X.2023.07.010.

[39] Liu SX, Zhang Y, Wang YF, Li XC, Xiang MX, Bian C, et al. Upregulation of heme oxygenase-1 expression by hydroxysafflor yellow A conferring protection from anoxia/reoxygenation-induced apoptosis in H9c2 cardiomyocytes. Int J Cardiol 2012; 160(2):95-101. doi:10.1016/j.ijcard. 2011.03.033, PMID:21497407.

[40] Zhang Y, Xiao J, Xu Y, Li J, Kao GY. Effects of hydroxysafflower yellow A on the proliferation and apoptosis of hypoxic/reoxygenated cardiomyocytes. Chin J Clin Pharmacol 2020; 36(24):3995-3998. doi:10.13699/j.cnki.1001-6821.2020.24.008.

[41] Huang P, Zhou W, Chen H, Zhou H, Duan S, Wan H, et al. Optimized separation of anhydrosafflor yellow B from safflower by high-speed counter-current chromatography and evaluation of its cardio-protective effect. Food Funct 2021; 12(19):9360-9371. doi:10.1039/ d1fo01767e, PMID:34606545.

[42] Zhao F, Cheng W, Wu D, Gong ZP, Ma WM, Xu J, et al. Hydroxysafflor yellow A ameliorates myocardial ischemia/reperfusion injury by promoting MDH1-mediated mitochondrial metabolic homeostasis. Phytomedicine 2025;144:156868. doi:10.1016/j.phymed.2025.156868, PMID:40513321.

[43] Liu YN, Zhou ZM, Chen P. Evidence that hydroxysafflor yellow A protects the heart against ischaemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening. Clin Exp Pharmacol Physiol 2008; 35(2):211-216. doi:10.1111/j.1440-1681.2007.04814.x, PMID:17941891.

[44] Min J, Wei C. Hydroxysafflor yellow A cardioprotection in ischemiareperfusion (I/R) injury mainly via Akt/hexokinase II independent of ERK/GSK-3β pathway. Biomed Pharmacother 2017; 87:419-426. doi:10.1016/j.biopha.2016.12.113, PMID:28068632.

[45] Ge C, Meng D, Peng Y, Huang P, Wang N, Zhou X, et al. The activation of the HIF-1α-VEGFA-Notch1 signaling pathway by Hydroxysafflor yellow A promotes angiogenesis and reduces myocardial ischemiareperfusion injury. Int Immunopharmacol 2024;142(Pt A):113097. doi:10.1016/j.intimp.2024.113097, PMID:39260311.

[46] Ge C, Peng Y, Li J, Wang L, Zhu X, Wang N, et al. Hydroxysafflor Yellow A Alleviates Acute Myocardial Ischemia/Reperfusion Injury in Mice by Inhibiting Ferroptosis via the Activation of the HIF-1α/SLC7A11/ GPX4 Signaling Pathway. Nutrients 2023; 15(15):3411. doi:10.3390/ nu15153411, PMID:37571350.

[47] Liang W, Zhang M, Gao J, Huang R, Cheng L, Zhang L, et al. Safflower Yellow Injection Alleviates Myocardial Ischemia/Reperfusion Injury by Reducing Oxidative and Endoplasmic Reticulum Stress. Pharmaceuticals (Basel) 2024; 17(8):1058. doi:10.3390/ph17081058, PMID:39204163.

[48] Xue X, Deng Y, Wang J, Zhou M, Liao L, Wang C, et al. Hydroxysafflor yellow A, a natural compound from Carthamus tinctorius L with good effect of alleviating atherosclerosis. Phytomedicine 2021;91:153694. doi:10.1016/j.phymed.2021.153694, PMID:34403879.

[49] Bao QL. Efficacy of safflower yellow sodium chloride injection combined with trimetazidine in the treatment of unstable angina pectoris and its effect on blood lipids levels and atherosclerotic plaques. Chin J Gerontol 2018; 38(22):5386-5388. doi:10.3969/j.issn.1005-9202.2018.22.004.

[50] Zhang H, Fan LJ, Liu J, Zhu JQ, Tan TT, Li M, et al. Safflor yellow A protects vascular endothelial cells from ox-LDL-mediated damage. J Recept Signal Transduct Res 2022; 42(1):52-59. doi:10.1080/107998 93.2020.1843492, PMID:33167774.

[51] Sheng L, Bi SJ, Jiao B, Ma WH. Inhibitory effect of hydroxy-safflor yellow A on proliferation of vascular smooth muscle cells stimulated by oxidized low-density lipoprotein. Chin J Pharmacol Toxicol 2012; 26(2):194-199. doi:10.3867/j.issn.1000-3002.2012.02.013.

[52] Ye F, Wang J, Meng W, Qian J, Jin M. Proteomic investigation of effects of hydroxysafflor yellow A in oxidized low-density lipoproteininduced endothelial injury. Sci Rep 2017; 7(1):17981. doi:10.1038/ s41598-017-18069-4, PMID:29269856.

[53] Ji DB, Zhu MC, Zhu B, Zhu YZ, Li CL, Ye J, et al. Hydroxysafflor yellow A enhances survival of vascular endothelial cells under hypoxia via upregulation of the HIF-1 alpha-VEGF pathway and regulation of Bcl- 2/Bax. J Cardiovasc Pharmacol 2008; 52(2):191-202. doi:10.1097/ FJC.0b013e318181fb02, PMID:18670359.

[54] Lian ZQ, Zhao DL, Zhu HB. Hydroxysafflor yellow A up-regulates HIF- 1alpha via inhibition of VHL and p53 in Eahy 926 cell line exposed to hypoxia. Yao Xue Xue Bao 2008; 43(5):484-489. PMID:18717335.

[55] Yang XP, Zhen ZM, Yu X, Liu TY, Shi HF, Zhu MM. Inhibition of hydroxysafflor yellow A on apoptosis of endothelial cells EA.hy 926 after hypoxia-reoxygenation. Chin Tradit Herb Drugs 2019; 50(16):3897-3903. doi:10.7501/j.issn.0253-2670.2019.16.023.

[56] Liu Y, Piao J, He J, Su Z, Luo Z, Luo D. Hydroxysafflor yellow A, a natural food pigment, ameliorates atherosclerosis in ApoE(-/-) mice by inhibiting the SphK1/S1P/S1PR3 pathway. Food Sci Nutr 2024; 12(11):8939-8955. doi:10.1002/fsn3.4466, PMID:39620014.

[57] Chen W, Schilperoort M, Cao Y, Shi J, Tabas I, Tao W. Macrophagetargeted nanomedicine for the diagnosis and treatment of atherosclerosis. Nat Rev Cardiol 2022; 19(4):228-249. doi:10.1038/s41569- 021-00629-x, PMID:34759324.

[58] Feng X, Du M, Li S, Zhang Y, Ding J, Wang J, et al. Hydroxysafflor yellow A regulates lymphangiogenesis and inflammation via the inhibition of PI3K on regulating AKT/mTOR and NF-κB pathway in macrophages to reduce atherosclerosis in ApoE-/- mice. Phytomedicine 2023;112:154684. doi:10.1016/j.phymed.2023.154684, PMID:36738477.

[59] Zhao T, Tu MT, Zheng CC, Lu QW, Luo S, Wan Q. Research Progress on the Regulation of Macrophage Autophagy in Atherosclerosis. China Modern Doctor 2024; 62(25):117-120. doi:10.3969/j.issn.1673-9701.2024.25.027.

[60] Li YL, Yang AN, Sun Y, Liu DY, You PD, Zeng YL, et al. Hydroxysafflor yellow A-loaded biomimetic liposomes alleviate HHcy-induced atherosclerosis by regulating methylation related autophagy. Mater Des 2023;227:111807. doi:10.1016/j.matdes.2023.111807.

[61] Liu YG, Li FJ. Protective effect of hydroxy-safflor yellow A on human umbilical vein endothelial cell apoptosis induced by angiotensin II. Zhong Yao Cai 2013; 36(7):1128-1131. PMID:24417152.

[62] Ji DB, Zhang LY, Li CL, Ye J, Zhu HB. Effect of Hydroxysafflor yellow A on human umbilical vein endothelial cells under hypoxia. Vascul Pharmacol 2009; 50(3-4):137-145. doi:10.1016/j.vph.2008.11.009, PMID:19084079.

[63] Song Y, Zhang L, Qu K, Li CL, Zhu HB. Hydroxysafflor Yellow A Promotes Vascular Endothelial Cell Proliferation via VEGF/VEGF Receptor. J Chin Pharm Sci 2005; 14(3):181-185.

[64] Fang F, Zhang W, Yang L, Wang Z, Liu DG. PECAM-1 and E-selectin expression in vulnerable plague and their relationships to myocardial Leu125Val polymorphism of PECAM-1 and Ser128Arg polymorphism of E-selectin in patients with acute coronary syndrome. Zhonghua Xin Xue Guan Bing Za Zhi 2011;39(12):1110-1116. doi:10.3760/cma.j.issn.0253-3758.2011.12.007, PMID:22336504.

[65] He W, Chen H, Zhu MM, Yang XP, Yu S, Shi HF. NF-κB Signaling Pathway Mediates the Protective Effect of Hydroxy Safflor Yellow A on TNF-α Induced Endothelial Cell EA. hy926 Injury. Acta Chin Med 2023; 38(2):351-359. doi:10.16368/j.issn.1674-8999.2023.02.061.

[66] Jin M, Sun CY, Zang BX. Hydroxysafflor yellow A attenuate lipopolysaccharide- induced endothelium inflammatory injury. Chin J Integr Med 2016; 22(1):36-41. doi:10.1007/s11655-015-1976-x, PMID:260 15073.

[67] Liu JL, Wang HF, Ma SH, Huo XP, Liang DY, Cao QW, et al. Hydroxysafflower Yellow A Exerts Anti-inflammatory Effects by Inhibiting the TNFR1/NF-κB Signaling Pathway in Arterial Endothelial Cells. Chin J Cell Mol Immunol 2015; 31(7):945-948. doi:10.13423/j.cnki. cjcmi.007393.

[68] Li XT, Wang YH, Zhou JY, Li P. Advances in Coronary Heart Disease Risk Factors Research. Xinjiang Journal of Traditional Chinese Medicine 2023; 41(3):97-101.

[69] Li YH, Zeng Q, Zhang JF, Huang XH, Wang Y. Research Progress on Obesity and Metabolic Syndrome. Chron Pathematol J 2018; 19(8):1038-1042.

[70] Zhu HJ, Wang X, Q Pan H, Dai YF, Li NS, Wang LJ, et al. The mechanism by which safflower yellow decreases body fat mass and improves insulin sensitivity in HFD-induced obese mice. Front Pharmacol 2016;7:127. doi:10.3389/fphar.2016.00127.

[71] Liu J, Yue S, Yang Z, Feng W, Meng X, Wang A, et al. Oral hydroxysafflor yellow A reduces obesity in mice by modulating the gut microbiota and serum metabolism. Pharmacol Res 2018; 134:40-50. doi:10.1016/j.phrs.2018.05.012, PMID:29787870.

[72] Lyu X, Yan K, Hu W, Xu H, Guo X, Zhou Z, et al. Safflower yellow and its main component hydroxysafflor yellow A alleviate hyperleptinemia in diet-induced obesity mice through a dual inhibition of the GIP-GIPR signaling axis. Phytother Res 2024; 38(10):4940-4956. doi:10.1002/ptr.7788, PMID:36943416.

[73] Yan K, Wang X, Pan H, Wang L, Yang H, Liu M, et al. Safflower Yellow and Its Main Component HSYA Alleviate Diet-Induced Obesity in Mice: Possible Involvement of the Increased Antioxidant Enzymes in Liver and Adipose Tissue. Front Pharmacol 2020;11:482. doi:10.3389/fphar.2020.00482, PMID:32372961.

[74] Liu XT, Zhang PL, Li P, Wen XD, Li Y. Advances in the Study on the Improvement of Heart and Brain Diseases by Safflower Hydroxyl Yellow A. Chinese Wild Plant Resources 2021; 40(8):53-60. doi:10.3969/j. issn.1006-9690.2021.08.010.

[75] Chen T, Chen N, Pang N, Xiao L, Li Y, Li R, et al. Hydroxysafflor Yellow A Promotes Angiogenesis via the Angiopoietin 1/ Tie-2 Signaling Pathway. J Vasc Res 2016; 53(5-6):245-254. doi:10.1159/000452408, PMID:27894114.

[76] Wang N, He D, Zhou Y, Wen J, Liu X, Li P, et al. Hydroxysafflor yellow A actives BK(Ca) channels and inhibits L-type Ca channels to induce vascular relaxation. Eur J Pharmacol 2020;870:172873. doi:10.1016/j. ejphar.2019.172873, PMID:31866408.

[77] Liu L, Cui Q, Song J, Yang Y, Zhang Y, Qi J, et al. Hydroxysafflower Yellow A Inhibits Vascular Adventitial Fibroblast Migration via NLRP3 Inflammasome Inhibition through Autophagy Activation. Int J Mol Sci 2022; 24(1):172. doi:10.3390/ijms24010172, PMID:36613617.

[78] Song DX, Jiang JG. Hypolipidemic Components from Medicine Food Homology Species Used in China: Pharmacological and Health Effects. Arch Med Res 2017; 48(7):569-581. doi:10.1016/j.arcmed. 2018.01.004, PMID:29452699.

[79] Hurt-Camejo E. ANGPTL3, PCSK9, and statin therapy drive remarkable reductions in hyperlipidemia and atherosclerosis in a mouse model. J Lipid Res 2020; 61(3):272-274. doi:10.1194/jlr.C120000650, PMID:31980481.

[80] Tyrrell DJ, Blin MG, Song J, Wood SC, Zhang M, Beard DA, et al. Age-Associated Mitochondrial Dysfunction Accelerates Atherogenesis. Circ Res 2020; 126(3):298-314. doi:10.1161/CIRCRESAHA.119.315644, PMID:31818196.

[81] Wang YF. The Influence of safflower yellow pigments (Letan) on the Changes of Blood Lipids and C-reactive Protein in Patients with Coronary Heart Disease. China Prac Med 2012; 7(15):149-150.

[82] Wu HX, Li J. Treatment of 100 Cases of Hyperlipidemia with safflower yellow pigments Powder for Injection. Journal of Practical Traditional Chinese Medicine 2011; 27(8):543.

[83] Bao LD, Wang Y, Ren XH, Ma RL, Lv HJ, Agula B. Hypolipidemic effect of safflower yellow and primary mechanism analysis. Genet Mol Res 2015; 14(2):6270-6278. doi:10.4238/2015.June.9.14, PMID:26125829.

[84] Lin B, Wan H, Yang J, Yu L, Zhou H, Wan H. Lipid regulation of protocatechualdehyde and hydroxysafflor yellow A via AMPK/SREBP2/ PCSK9/LDLR signaling pathway in hyperlipidemic zebrafish. Heliyon 2024; 10(3):e24908. doi:10.1016/j.heliyon.2024.e24908, PMID:383 33845.

[85] Jin M, Gao ZC, Wang JF. Research on the Inhibitory Effects of Hydroxysafflor Yellow A on the Rabbit Platelet Activation Induced by Platelet Activating Factor. Journal of Beijing University of TCM 2004; 5:32-35.

[86] Chen WM, Jin M, Wu W, Li JR, Yang SD. Inhibition of safflor yellow on rabbit platelet activation induced by platelet activating factor. Chin Pharm J 2000; 35(11):741-744. doi:10.3321/j.issn:1001-2494.2000.11.009.

[87] Huang W, Yao W, Weng Y, Xie X, Jiang J, Zhang S, et al. Hydroxysafflor yellow A inhibits the hyperactivation of rat platelets by regulating the miR-9a-5p/SRC axis. Arch Biochem Biophys 2023;747:109767. doi:10.1016/j.abb.2023.109767, PMID:37748625.

[88] Lee M, Li H, Zhao H, Suo M, Liu D. Effects of Hydroxysafflor Yellow A on the PI3K/AKT Pathway and Apoptosis of Pancreatic β-Cells in Type 2 Diabetes Mellitus Rats. Diabetes Metab Syndr Obes 2020; 13:1097-1107. doi:10.2147/DMSO.S246381, PMID:32308459.

[89] Zhao Y, Sun H, Li X, Zha Y, Hou W. Hydroxysafflor yellow A attenuates high glucose-induced pancreatic β-cells oxidative damage via inhibiting JNK/c-jun signaling pathway. Biochem Biophys Res Commun 2018; 505(2):353-359. doi:10.1016/j.bbrc.2018.09.036, PMID: 30249395.

[90] Rong J, Li C, Zhang Q, Zheng G, Fan W, Pan Z, et al. Hydroxysafflor yellow A inhibits endothelial cell ferroptosis in diabetic atherosclerosis mice by regulating miR-429/SLC7A11. Pharm Biol 2023; 61(1):404-415. doi:10.1080/13880209.2023.2225543, PMID:37410531.

[91] Wu L, Kang A, Yue SJ, Tang YP. Research Progress on the In-Vivo Process of Hydroxysafflor Yellow A. Chinese Traditional Patent Medicine 2020; 42(1):150-155. doi:10.3969/j.issn.1001-1528.2020.01.032.

[92] Huang ML, Song HP, Pang HQ, Gao W, Wen X. Research Progress of the Pharmacokinetics of Safflor Yellow Pigments. Pharmaceutical and Clinical Research 2018; 26(4):287-290. doi:10.13664/j.cnki. pcr.2018.04.012.

[93] Gao H, Zhou HM, Yue SJ, Feng LM, Guo DY, Li JJ, et al. Oral Bioavailability- Enhancing and Anti-obesity Effects of Hydroxysafflor Yellow A in Natural Deep Eutectic Solvent. ACS Omega 2022; 7(23):19225-19234. doi:10.1021/acsomega.2c00457, PMID:35721932.

[94] Liu H, Zhuang J, Tang P, Li J, Xiong X, Deng H. The Role of the Gut Microbiota in Coronary Heart Disease. Curr Atheroscler Rep 2020; 22(12):77. doi:10.1007/s11883-020-00892-2, PMID:33063240.

[95] Wu L, Tang Y, Shan C, Chai C, Zhou Z, Shi X, et al. A comprehensive in vitro and in vivo metabolism study of hydroxysafflor yellow A. J Mass Spectrom 2018; 53(2):99-108. doi:10.1002/jms.4041, PMID:29076598.

[96] Fan L, Pu R, Zhao HY, Liu X, Ma C, Wang BR, et al. Stability and degradation of hydroxysafflor yellow A and anhydrosafflor yellow B in the Safflower injection studied by HPLC-DAD-ESI-MSn. J Chin Pharm Sci 2011; 20(1):47-56. doi:10.5246/jcps.2011.01.007.